English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, September 10, 2019
知臨集團已啟動用於治療包括MRSA的金黃色葡萄球菌感染小分子候選藥物ALS-4的IND籌備研究
Aptorum Group has initiated IND-Enabling Studies for its ALS-4 Small Molecule Candidate for the Treatment of Infections Caused by Staphylococcus Aureus including MRSA
知臨集團宣布靶向肥胖症微生物組候選藥物和神經母細胞瘤再利用候選藥物的開發
Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
Monday, March 11, 2019
全球性流感带动医疗需求 知临集团把握机遇创造价值
全球性流感帶動醫療需求 知臨集團把握機遇創造價值
Friday, December 7, 2018
知临集团有限公司宣布首次公开发售定价
知臨集團有限公司宣佈首次公開發售定價
Aptorum Group Limited Announces Pricing of Initial Public Offering

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575